TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11226087

Group type: EXPERIMENTAL
Intervention: RSR13 (75 mg/kg and 100 mg/kg doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RSR13 (all doses)
Number of subjects: 26
Study: 10193229

Group type: EXPERIMENTAL
Intervention: Suction applied under sterile drapes to avoid rebreathing of CO2 (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No air suction used (Group A)
Number of subjects: 0
Study: 7845278

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plus 100 micrograms fentanyl
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.5% bupivacaine plus 50 micrograms fentanyl
Number of subjects: 31
Study: 3258222

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (10 ml/kg; n = 15) using hydroxyethyl starch solution (HES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated; n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups after ECC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HD group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 29471711

Group type: EXPERIMENTAL
Intervention: Preference-setting model for return of results regarding their child
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrower set of IRRs preference
Number of subjects: 0
Study: 28320482

Group type: EXPERIMENTAL
Intervention: Pressure relieving mattress (specific type not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photographic assessment of skin sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised camera and photographic technique
Number of subjects: 0
Study: 25778112

Group type: EXPERIMENTAL
Intervention: Vastus Medialis Muscle %Fat increase of 1%
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Vastus Medialis Muscle area decrease of 1%
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Concurrent presence of low VM area, high VM %Fat, and high BMI
Number of subjects: 143
Study: 23177418

Group type: EXPERIMENTAL
Intervention: Split-dose group (75 IU rHLH given as four equally divided doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Single-dose group (75 IU rHLH given as a single dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Split-dose group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Single-dose group
Number of subjects: 27
Study: 21653935

Group type: EXPERIMENTAL
Intervention: Behavioural intervention (motivational interviewing, provision of condoms, gloves, and water-based lubricant)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (general STI education)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 19657112

Group type: EXPERIMENTAL
Intervention: Higher plasma levels of sex hormone-binding globulin (SHBG)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Variant allele of SHBG SNP rs6259
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Variant allele of SHBG SNP rs6257
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Increase in plasma level of sex hormone-binding globulin (SHBG)
Number of subjects: 529
Study: 16920503

Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human GM-CSF (rhGM-CSF) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15309484

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11383355

Group type: EXPERIMENTAL
Intervention: 2 implants with ball attachment
Number of subjects: 110

Group type: COMPARATOR
Intervention: 2 implants interconnected with a bar
Number of subjects: 110

Group type: COMPARATOR
Intervention: 4 implants interconnected with bars
Number of subjects: 110
Study: 8996264

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel) at a dose of 0.5 ml three times a week for 2 weeks
Number of subjects: 122
Study: 7986856

Group type: COMPARATOR
Intervention: Group I (without lipid): received 100% of caloric intake (CI) by glucose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group II (LCT): received 55% of CI by glucose and 45% by LCT at 20% emulsion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group III (MCT/LCT): received 55% of CI by glucose and 45% by MCT/LCT at 20% mixture
Number of subjects: 21
Study: 3257376

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 34
Study: 30477846

Group type: EXPERIMENTAL
Intervention: Disease-specific suggestions (using counter-hyperarousal hypnotic exercise and screen visualization technique)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Generic suggestions (using thought distraction technique and suggestions for self-confidence and self-care enhancement)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 28556577

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 70% VO2 max
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition at 20% VO2 max
Number of subjects: 30
Study: 25909533

Group type: EXPERIMENTAL
Intervention: Implant-connected partial dentures
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tooth-connected partial dentures
Number of subjects: 20
Study: 23934169

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 5% human serum albumin (HSA)
Number of subjects: 55
Study: 16622463

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy (DD) with epirubicin 90 mg/m² plus paclitaxel 175 mg/m² in four 14-day cycles, followed by CMF 600/40/600 in three 14-day cycles, plus filgrastim 5 µg/kg/day
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional-schedule chemotherapy (CS) with epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² in four 21-day cycles, followed by CMF 600/40/600 in three 21-day cycles, plus filgrastim if required
Number of subjects: 216
Study: 14527816

Group type: EXPERIMENTAL
Intervention: Spiral X-ray computed tomography
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Registration technique to align spiral X-ray computed tomography data with pressure sensor data
Number of subjects: 18
Study: 10195613

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 1-6 days after measles vaccination
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 7-13 days after measles vaccination
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 14-21 days after measles vaccination
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 22-27 days after measles vaccination
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered >28 days after measles vaccination
Number of subjects: 294
Study: 8538116

Group type: EXPERIMENTAL
Intervention: 32 degrees C (tepid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 28 degrees C
Number of subjects: 100

Group type: COMPARATOR
Intervention: 30 degrees C
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 1962905

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (FR‐860)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (H‐25)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (F‐50)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (F‐25 and F‐35)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 10
Study: 6101748

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase, carcinoembryonic antigen, and gamma‐glutamyl transpeptidase tests
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clinical examination, chest X‐ray, and the three tumour markers
Number of subjects: 47
Study: 31884898

Group type: EXPERIMENTAL
Intervention: Jigsaw method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional small group method
Number of subjects: 0
Study: 29625777

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR) thrice weekly for 12 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tai Chi five times weekly for 12 weeks
Number of subjects: 120
Study: 28598826

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo (Vitamin E)
Number of subjects: 186

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 186
Study: 26302142

Group type: EXPERIMENTAL
Intervention: 6-month pharmacist intervention comprising collaborative care, medication review, and tailored adherence counseling including motivational interviewing and telephone follow-ups.
Number of subjects: 532

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: 6-month pharmacist intervention.
Number of subjects: 532
Study: 23208945

Group type: EXPERIMENTAL
Intervention: Classification-based cognitive functional therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Manual therapy and exercise
Number of subjects: 121
Study: 21406499

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intraarticular corticosteroid injections
Number of subjects: 34
Study: 18192510

Group type: EXPERIMENTAL
Intervention: High-dose senicapoc (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15708225

Group type: EXPERIMENTAL
Intervention: Bifid VEP in patients with demyelinating disease (90 patients)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Bifid VEP in healthy controls (50 persons)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bifid VEP in patients with unconfirmed suspicion for MS (26 patients)
Number of subjects: 116
Study: 14529061

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra®)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Open-label studies
Number of subjects: 120
Study: 10568568

Group type: EXPERIMENTAL
Intervention: Nitric-oxide-generating gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel (KY jelly only)
Number of subjects: 30
Study: 8947701

Group type: EXPERIMENTAL
Intervention: Personalized computer-based information
Number of subjects: 0

Group type: COMPARATOR
Intervention: General computer-based information
Number of subjects: 0
Study: 1751080

Group type: EXPERIMENTAL
Intervention: AN69S membrane dialyzers
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cellulosic dialyzers
Number of subjects: 49
Study: 7061569

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal adult volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with bad performance status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with stage III primary lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients after chemotherapy
Number of subjects: 0
Study: 30835326

Group type: EXPERIMENTAL
Intervention: Low-speed rotational atherectomy (RA) at 135,000 rpm with substantial debulking before stenting
Number of subjects: 889

Group type: COMPARATOR
Intervention: Non-RA treatment
Number of subjects: 889
Study: 29089056

Group type: EXPERIMENTAL
Intervention: Lotilaner (20-43 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham-treated control
Number of subjects: 28
Study: 26227783

Group type: EXPERIMENTAL
Intervention: 800 mg synthetic GABA
Number of subjects: 30

Group type: COMPARATOR
Intervention: 800 mg oral microcrystalline cellulose (placebo)
Number of subjects: 30
Study: 23038750

Group type: EXPERIMENTAL
Intervention: Polypill strategy (combining aspirin, a statin, and two blood pressure lowering agents)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2000
Study: 23342824

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 23

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 23
Study: 20137476

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (10 mg/kg daily for 7 days before surgery and 200 mg daily for 10 days postoperatively)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 210
Study: 17448696

Group type: EXPERIMENTAL
Intervention: Arthroscopic distal clavicle excision
Number of subjects: 17

Group type: COMPARATOR
Intervention: Open distal clavicle excision
Number of subjects: 17
Study: 15219661

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11575001

Group type: EXPERIMENTAL
Intervention: Soluble thrombomodulin concentration in lung cancer patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (adults)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Comparison between stages IB and IIIB
Number of subjects: 33
Study: 9833596

Group type: EXPERIMENTAL
Intervention: Racemic propafenone (150 mg every 6 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (S)‐propafenone (150 mg every 6 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (R)‐propafenone (150 mg every 6 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Racemic propafenone, (S)‐propafenone, (R)‐propafenone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Racemic propafenone, (S)‐propafenone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8589464

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Patient age, use of calcium channel blockers, presence of diabetes mellitus (DM)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Time on dialysis pre graft placement
Number of subjects: 79
Study: 2666363

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial local control with radiation therapy or radiation plus surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage therapy for metastatic disease
Number of subjects: 0
Study: 793437

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (HLI) 3 X 10(‐6) units/ml, two drops twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30700356

Group type: EXPERIMENTAL
Intervention: Trastuzumab with neoadjuvant chemotherapy (n=89, n=64 received complete standard dose)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy only (Control group, n=67)
Number of subjects: 156
Study: 28493519

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study: 25758676

Group type: EXPERIMENTAL
Intervention: Downhill walking (DW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Downhill walking with load (DWL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Level walking (LW)
Number of subjects: 10
Study: 22898654

Group type: EXPERIMENTAL
Intervention: Patient education program (6 sessions à 90 min)
Number of subjects: 261
Study: 22069954

Group type: EXPERIMENTAL
Intervention: Emospid
Number of subjects: 69

Group type: COMPARATOR
Intervention: MMDH
Number of subjects: 69
Study: 19176440

Group type: EXPERIMENTAL
Intervention: N-terminal BNP-guided therapy
Number of subjects: 499

Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 499
Study: 16573580

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acamprosate (ACP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both OXC and ACP
Number of subjects: 30
Study: 12754730

Group type: EXPERIMENTAL
Intervention: Nonpsychotic group nurses (read vignette with patient on alprazolam)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psychotic group nurses (read vignette with patient on haloperidol, benztropine, lorazepam, trazadone, fluoxetine, and lithium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group nurses (read vignette without psychiatric medication)
Number of subjects: 60
Study: 11286449

Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normotensive anaesthesia
Number of subjects: 53
Study: 9369825

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline sulfate (0.25 mg)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 179

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 179
Study: 1395634

Group type: EXPERIMENTAL
Intervention: TRUE Test
Number of subjects: 413

Group type: COMPARATOR
Intervention: Finn Chamber
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Both TRUE Test and Finn Chamber
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: TRUE Test only
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Finn Chamber only
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Relevant positive reactions
Number of subjects: 413
Study: 2859421

Group type: EXPERIMENTAL
Intervention: MOPP (mustine, vincristine, procarbazine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local involved-field irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic survival index (greater than 7.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age, sex, erythrocyte sedimentation (ESR), presence or absence of mediastinal involvement, pathological grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 0
Study: 31383978

Group type: EXPERIMENTAL
Intervention: Complementary food with rapeseed oil (IG-R)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Complementary food with oily fish (IG-F)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group with corn oil (CG)
Number of subjects: 160
Study: 30113750

Group type: EXPERIMENTAL
Intervention: VIB (40 Hz)
Number of subjects: 10

Group type: COMPARATOR
Intervention: TRAD (traditional HIT session without vibration)
Number of subjects: 10
Study: 27790772

Group type: EXPERIMENTAL
Intervention: Hydrogel contact lens
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel contact lens
Number of subjects: 103

Group type: COMPARATOR
Intervention: Symptomatic group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 103
Study: 24773760

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MIG) plus standard care (information sheet on glaucoma and its treatment)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 300
Study: 22466942

Group type: EXPERIMENTAL
Intervention: Auricular therapy combined with optimized Yinxieling Formula
Number of subjects: 84

Group type: COMPARATOR
Intervention: Optimized Yinxieling Formula alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 20184810

Group type: EXPERIMENTAL
Intervention: Generalized social phobia (GSP) patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 18517091

Group type: EXPERIMENTAL
Intervention: Neighborhood-based physical activity intervention
Number of subjects: 573
Study: 15951736

Group type: EXPERIMENTAL
Intervention: PTNS performed weekly (Group A)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PTNS performed 3 times per week (Group B)
Number of subjects: 35
Study: 11871949

Group type: EXPERIMENTAL
Intervention: intubating laryngeal mask‐blind group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: intubating laryngeal mask‐fibreoptic group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: laryngeal mask‐fibreoptic group
Number of subjects: 60
Study: 10600247

Group type: EXPERIMENTAL
Intervention: Alcohol (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matched drink)
Number of subjects: 0
Study: 7605835

Group type: EXPERIMENTAL
Intervention: TENS (monophasic pulse, small anode, large cathode, frequency 20 Hz) for 20 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional TENS (biphasic pulse, electrodes of identical size, frequency 100 Hz) for 20 min
Number of subjects: 50
Study: 2220647

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy combined with one of five active drug regimens (acebutolol, amlodipine, chlorthalidone, doxazosin, enalapril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpharmacologic treatment only
Number of subjects: 0
Study: 93353

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (1.0 up to 1.5 g/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Metizol (thiamazol) 60 mg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Combined therapy with lithium and metizol
Number of subjects: 65
Study: 6979347

Group type: EXPERIMENTAL
Intervention: Diprivan alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diprivan and fentanyl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl with diprivan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propanidid and fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thiopentone and halothane
Number of subjects: 80
Study: 30866886

Group type: EXPERIMENTAL
Intervention: Physical Activity Traditional Style
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Physical Activity Need-Supportive Style
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Theatre condition
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 140
Study: 30297017

Group type: EXPERIMENTAL
Intervention: 2D Portion Size Estimation Aids (PSEAs)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 3D Portion Size Estimation Aids (PSEAs)
Number of subjects: 37